Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Revenue (2016 - 2025)

Historic Revenue for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $27.8 million.

  • Anika Therapeutics' Revenue fell 589.33% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 3055.34%. This contributed to the annual value of $119.9 million for FY2024, which is 73.27% down from last year.
  • As of Q3 2025, Anika Therapeutics' Revenue stood at $27.8 million, which was down 589.33% from $28.2 million recorded in Q2 2025.
  • Anika Therapeutics' Revenue's 5-year high stood at $44.3 million during Q2 2023, with a 5-year trough of -$2.9 million in Q4 2023.
  • Over the past 5 years, Anika Therapeutics' median Revenue value was $34.3 million (recorded in 2021), while the average stood at $30.8 million.
  • In the last 5 years, Anika Therapeutics' Revenue plummeted by 10778.04% in 2022 and then skyrocketed by 115560.54% in 2024.
  • Quarter analysis of 5 years shows Anika Therapeutics' Revenue stood at $35.8 million in 2021, then plummeted by 107.78% to -$2.8 million in 2022, then fell by 4.02% to -$2.9 million in 2023, then skyrocketed by 1155.61% to $30.6 million in 2024, then fell by 9.1% to $27.8 million in 2025.
  • Its last three reported values are $27.8 million in Q3 2025, $28.2 million for Q2 2025, and $26.2 million during Q1 2025.